Document:

Exhibit 10.1

 

This PREFERRED STOCK REPURCHASE AGREEMENT
(this “Agreement”) dated as of March 14, 2019, among BioScrip, Inc. (the “Company”)
on the one hand and Coliseum Capital Partners, L.P., Coliseum Capital Partners II, L.P. and Blackwell Partners LLC – Series
A, on the other hand (each a “Preferred Stockholder” and collectively, the “Preferred Stockholders”).

 

WHEREAS, the Preferred Stockholders collectively
own 614,177 shares (the “Preferred Shares”) of Series C Convertible Preferred Stock, par value $0.0001 per share,
of the Company (the “Series C Preferred Stock”) representing 100% of the outstanding Series C Preferred Stock;

 

WHEREAS, the Company and the Preferred Stockholders
are party to that certain Registration Rights Agreement, dated March 9, 2015, as amended by that certain Amendment No. 1 to the
Registration Rights Agreement, dated June 10, 2016 and that certain Amendment No. 2 to the Registration Rights Agreement, dated
June 14, 2016 (the “Registration Rights Agreement”);

 

WHEREAS, the Preferred Stockholders desire
to sell to the Company the Preferred Shares and the Company desires to repurchase the Preferred Shares; and

 

WHEREAS, on the date hereof, the Company
is entering into that certain Agreement and Plan of Merger by and among the Company, HC Group Holdings I, LLC, a Delaware limited
liability company (“Omega Parent”), HC Group Holdings II, Inc.. a Delaware corporation (“Omega”),
HC Group Holdings III, Inc., a Delaware corporation, Beta Sub, Inc., a Delaware corporation, and Beta Sub, LLC, a Delaware limited
liability company (as amended or modified, the “Merger Agreement”).

 

NOW, THEREFORE, in consideration of the
premises and of the mutual representations, warranties and covenants contained herein, the parties hereby agree as follows:

 

1.             
Sale and Repurchase of the Shares. Subject to the terms of this Agreement, at the Repurchase Closing (as defined
below),the Company shall repurchase and acquire from the Preferred Stockholders, and each of the Preferred Stockholders shall sell,
assign, deliver and convey to the Company (the “Repurchase”), the Preferred Shares listed next to such Preferred
Stockholder’s name on Schedule 1 to this Agreement for a purchase price of (i) an amount in cash equal to 120% of the Liquidation
Preference (as defined in the Certificate of Designations of Series C Convertible Preferred Stock of the Corporation (the
“COD”)) per Preferred Share determined as of the date of the Repurchase Closing (the “Cash Repurchase
Price”) and (ii) 2.5226 fully paid, validly issued and non-assessable shares of Common Stock of the Company, $0.0001
par value per share (the “Common Stock”), per Preferred Share (the “Share Repurchase Consideration”
and together with the Cash Repurchase Price, the “Repurchase Price”). For purposes of clause (i) of this Section
1, in the event the Repurchase Closing occurs on a date during a Regular Dividend Period (as defined in the COD), the Liquidation
Preference per Preferred Share shall include Accrued Dividends (in addition to all prior Accrued Dividends) calculated in accordance
with Section 3(a)(ii) of the COD for such partial period. Such Repurchase Price shall be paid in full satisfaction of all obligations
of the Company to the Preferred Stockholders with respect to the Preferred Shares (including, without limitation, all dividends
accrued thereon in accordance with the COD) but unpaid).

 

     

     

    

 

2.             
Closing. The Repurchase described and provided for in this Agreement shall take place at a closing (the “Repurchase
Closing”) at the offices of Gibson, Dunn & Crutcher, LLP at 200 Park Avenue, New York, New York immediately
following the Second Merger Effective Time (as defined in the Merger Agreement) or such other date as each of the parties hereto,
with the prior written consent of Omega, agrees in writing. Each Preferred Stockholder’s obligations to sell its Preferred
Shares under this Agreement shall be conditioned upon the Repurchase Closing occurring at or prior to February 11, 2020. At the
Repurchase Closing:

 

(a)          
the Preferred Stockholders hereby agree to take such action as may reasonably be requested or as may be required to have
the Company’s transfer agent record the transfer of the Preferred Shares in the Company’s share registry; and

 

(b)          
subject to receipt by the Company of the certificates described in clause (a) above, the Company shall (i) deliver to each
of the Preferred Stockholders an amount equal to the Cash Repurchase Price multiplied by the number of Preferred Shares being sold
to the Company by the applicable Preferred Stockholder by check or wire transfer in immediately available funds to a bank account
designated by the Preferred Stockholders prior to the date thereof and (ii) issue to each of the Preferred Stockholders that number
of shares of Common Stock equal to the Share Repurchase Consideration multiplied by the number of Preferred Shares being sold to
the Company by the applicable Preferred Stockholder.

 

3.             
Representations and Warranties of the Stockholders. Each Preferred Stockholder represents and warrants to the Company
as to itself as follows:

 

(a)  
Such Preferred Stockholder is the legal and beneficial owner of the Preferred Shares listed next to such Preferred Stockholder’s
name on Schedule 1 to this Agreement. Each Preferred Stockholder owns such Preferred Shares outright and free and clear of any
options, contracts, agreements, liens, security interests, mortgages, pledges, charges, equities, claims or restrictions on transferability
or encumbrances of any kind, or other encumbrances.

 

(b)              
The Preferred Shares listed on Schedule 1 represent all of the Series C Preferred Stock beneficially owned by the Preferred
Stockholder.

 

(c)              
It has all requisite power and authority to sell and transfer the Preferred Shares to the Company in the manner provided
herein.

 

(d)              
It has the right, power, legal capacity and authority to enter into and perform its obligations under this Agreement, and
has obtained all required consents or approvals necessary for the execution, delivery and performance by it of this Agreement.
This Agreement has been duly executed and delivered by it, and constitutes its valid and binding obligation enforceable in accordance
with its terms (except to the extent that enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium,
fraudulent transfer or other similar laws relating to creditors’ rights generally or by general principles of equity and
public policy).

 

    	 	2	 

     

    

 

(e)              
As of March 14, 2019, the Liquidation Preference (including Accrued Dividends) with respect to the Preferred Shares is $157.746
per Preferred Share and $96,883,945 in the aggregate.

 

4.             
Representations and Warranties of the Company. The Company represents and warrants to the Preferred Stockholder as
follows:

 

(a)              
The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware.

 

(b)              
The Company has the corporate power and authority to enter into this Agreement and to perform its obligations hereunder.
This Agreement constitutes the valid and binding obligation of the Company enforceable in accordance with its terms (except to
the extent that enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer or other
similar laws relating to creditors’ rights generally or by general principles of equity and public policy).

 

(c)              
The Board of Directors of the Company has approved the execution and delivery of this Agreement and the consummation of
the transactions hereunder.

 

(d)              
At the Repurchase Closing, the Company will have duly authorized a sufficient number of shares of Common Stock to consummate
the Repurchase Closing, and when issued, all shares of Common Stock issued as Share Repurchase Consideration under this Agreement
will be fully paid, validly issued and non-assessable, and not subject to any transfer restrictions other than pursuant to applicable
law, and no stockholder of the Company will have any preemptive right of subscription or purchase in respect thereof.

 

(e)              
At the Repurchase Closing, the Company’s repurchase of the Preferred Shares under this Agreement will comply with
Section 160 of the General Corporation Law of the State of Delaware.

 

(f)   
As of March 14, 2019, the Liquidation Preference (including Accrued Dividends) with respect to the Preferred Shares is $157.746
per Preferred Share and $96,883,945 in the aggregate.

 

5.             
No Transfers or Conversions. Following the execution hereof and until the Repurchase Closing, each of the Preferred
Stockholders agrees not to, and to cause its affiliates not to, (i) directly or indirectly, sell, transfer, assign, pledge, tender,
convert, exchange or encumber or otherwise dispose of any of the Preferred Shares or (ii) exercise its right to convert the Preferred
Shares into shares of Common Stock pursuant to Section 6 of the COD.

 

6.             
Termination. This Agreement (other than Sections 6, 9 and 13-24, which shall survive the termination) shall terminate
automatically and shall have no further force and effect as of the earliest to occur of (i) such date and time as the Merger Agreement
shall be validly terminated in accordance with the terms and provisions thereof, and (ii) the effectiveness of a written agreement
executed by the parties hereto and Omega to terminate this Agreement. Upon termination or expiration of this Agreement, no party
shall have any further obligations or liabilities under this Agreement (other than Sections 6, 9 and 13-24, which shall survive
the termination); provided, however, that such termination or expiration shall not relieve any party from liability
for any willful and material breach of this Agreement prior to termination or expiration thereof. “Business Day”
means any day other than a Saturday, a Sunday or a day on which banks in New York, New York or Chicago, Illinois are authorized
or required by applicable law to be closed.

 

    	 	3	 

     

    

 

7.             
Registration Rights Waiver. The execution and delivery of this Agreement by the Preferred Stockholders, which represent
a Majority-in-Interest (as defined in the Registration Rights Agreement) of the Holders (as defined in the Registration Rights
Agreement) under the Registration Rights Agreement, shall be deemed a consent by the Preferred Stockholders, in their capacities
as Holders, under Section 9 (Preservation of Rights) of the Registration Rights Agreement with respect to the registration rights
to be granted to Omega Parent in connection with the Merger Agreement and any reverse stock splits that may be effected by the
Company following the Repurchase Closing.

 

8.                 
Waiver of Rights. The execution and delivery of this Agreement by the Company and the Preferred Stockholders shall
constitute the express waiver by the Preferred Stockholders of any right, notice, consent, entitlement or other procedural requirement
arising as a result of the share issuances and other transactions contemplated by the Merger Agreement, under the Second Amended
and Restated Certificate of Incorporation of the Company, as amended, the Amended and Restated Bylaws of the Company and the COD,
in each case, that may be applicable to, and inconsistent with, the transactions contemplated by this Agreement or the Merger Agreement,
including its right to convert the Preferred Shares into shares of Common Stock pursuant to Section 6 of the COD.

 

9.                 
Indemnification.

 

(a)  
The Company shall indemnify, defend and hold harmless the Preferred Stockholders and each officer, director, member, partner,
affiliate, employee, agent and representative of the Preferred Stockholders (collectively, the “Stockholder Indemnitees”)
against all claims, actions, judgments, liabilities, losses, and damages, together with all reasonable and properly documented
costs and expenses related thereto (including reasonable legal fees and expenses, collectively, “Losses”)) relating
to or arising from (i) the execution or delivery of this Agreement, the Repurchase Closing or the performance by any Preferred
Stockholder of its obligations under this Agreement, or (ii) the execution and delivery of the voting agreement entered into by
the Preferred Stockholders with Omega Parent and Omega relating to the Merger Agreement (the “Voting Agreement”)
or the performance by any Preferred Stockholder of its obligations under the Voting Agreement, in each case except to the extent
that any such Losses are attributable to the breach of this Agreement or the Voting Agreement by the Preferred Stockholder or the
willful misconduct or fraud of such Stockholder Indemnitee. In the event that any Stockholder Indemnitee claims any such right
of indemnification, such Stockholder Indemnitee shall provide to the Company prompt written notice thereof, together with reasonable
detail regarding such claims (provided that the failure to so notify shall not relieve the Company from its obligations under this
Section 9 except to the extent that the Company forfeits rights or defenses by reason of such failure) and in the event such claims
involved third party claims, allow the Company to defend and settle such claims on the Stockholder Indemnitee’s behalf; provided,
however, that the Company shall keep the Stockholder Indemnitee reasonably apprised of the status of the defense of any
such third party claim and such Stockholder Indemnitee shall have the right to participate in such defense and to employ counsel
of its choice for such purpose, and the fees and expenses of such separate counsel shall be borne by the Stockholder Indemnitee,
except that such fees and expenses (to the extent reasonable, documented and out-of-pocket) shall be borne by the Company (i) to
the extent incurred prior to the date the Company assumed control of such defense, (ii) if the Stockholder Indemnitee reasonably
shall have concluded (upon advice of its counsel) that there may be one or more legal defenses available to such Stockholder Indemnitee
that cannot reasonably be asserted by the Company on behalf of the Stockholder Indemnitee, in which case the fees and expenses
(to the extent reasonable, documented and out-of-pocket) incurred by the Stockholder Indemnitee in asserting any such legal defenses
shall be borne by the Company, or (iii) if the Stockholder Indemnitee reasonably shall have concluded (upon advice of its counsel)
that the Company has conflicting legal positions from the Stockholder Indemnitee with respect to such third party claims or that
representation of such Stockholder Indemnitee by the counsel retained by the Company would be inappropriate due to actual or potential
differing interests between such Stockholder Indemnitee and any other party represented by such counsel with respect to such third
party claim, in which case the Company shall not have the right to assume the defense of such claims against the Stockholder Indemnitee
and all fees and expenses (to the extent reasonable, documented and out-of-pocket) incurred by the Stockholder Indemnitee in connection
with such third party claims shall be indemnified by the Company. If the Company fails to assume the defense of any claims in accordance
with the above, the Stockholder Indemnitee shall have the sole right to defend and settle any such third party claims; provided
that such right to settle shall be subject to the prior written consent of the Company (not to be unreasonably conditioned, delayed
or withheld). Except as provided above, the Company shall promptly reimburse each Stockholder Indemnitee for any reasonable and
properly documented legal and any other necessary out-of-pocket expenses incurred by such Stockholder Indemnitee in connection
with investigating and defending any such Losses. The Company agrees that it will not, without the Stockholder Indemnitee’s
prior written consent, settle or compromise any claim or consent to entry of any judgment in respect thereto in any pending or
threatened action, suit, claim or proceeding in respect of which indemnification has been sought hereunder unless such settlement
or compromise does not require the payment of money by such Stockholder Indemnitee, does not impose any other obligation on such
Stockholder Indemnitee, does not subject such Stockholder Indemnitee to any injunction or restrictive covenants, and includes an
unconditional release of such Stockholder Indemnitee from all liability arising out of such action, suit, claim or proceeding.
As of the date hereof, the Preferred Stockholders are not aware of any occurrences, events or circumstances that would reasonably
be expected to result in a claim for indemnification under this Section 9. The obligations under this Section 9 shall survive the
consummation of the transactions contemplated by this Agreement.

    	 	4	 

     

    

 

 

(b)  
The foregoing right to indemnity and advancement of expenses shall be in addition to any rights that the Stockholder Indemnitee
may have at common law, pursuant to contract or otherwise (both as to action in his or its official capacity and as to action in
another capacity while holding such position or related to the Company). Each of the parties hereto acknowledges that certain Stockholder
Indemnitees may have certain rights to indemnification, advancement of expenses and/or insurance provided by the the Preferred
Stockholder or the affiliates of a Preferred Stockholder (collectively, the “Other Indemnitors”) and hereby
agrees that the Company and its affiliates are, collectively, the indemnitor of first resort (it being understood, for the avoidance
of doubt, that the obligations of the Other Indemnitor, if any, are secondary and any obligation of the Company to provide indemnification
(including, without limitation, through director or officer insurance policies) for the same expenses or liabilities incurred by
the Stockholder Indemnitees are primary).

 

10.             
Warrant Acknowledgment and Agreement. The execution and delivery of this Agreement by the Preferred Stockholders
shall constitute the express acknowledgment by and agreement of the Preferred Stockholders that any Warrant Certificates (as defined
in the 2015 Warrant Agreement) issued pursuant to the 2015 Warrant Agreement (a) are not entitled to any antidilution or other
adjustments as of the date hereof and (b) shall not be subject to any antidilution or other adjustments arising as a result of
the share issuances and other transactions contemplated by the Merger Agreement, this Agreement and that certain letter agreement,
dated as of the date hereof, between the Company and ASSF IV AIV B Holdings, L.P., including any adjustments to the Exercise Price
(as defined in the 2015 Warrant Agreement) of such Warrant Certificates pursuant to Section 4 of the 2015 Warrant Agreement. For
purposes of this Agreement, “2015 Warrant Agreement” means that certain Warrant Agreement, dated as of March
9, 2015, by and among the Company and the purchasers party thereto. For the avoidance of doubt, the 2015 Warrant Agreement and
Warrant Certificates issued thereunder shall remain in full force and effect following the Repurchase Closing. The Company and
the Preferred Stockholders agree that this Section 10 constitutes an amendment of the 2015 Warrant Agreement and that they shall
take such actions as may be reasonably requested by another party or Omega to effectuate such amendment.

 

11.             
Release. Effective (i) as of the Repurchase Closing with respect to Series C Preferred Stock, and (ii) as of the
date of redemption with respect to Series A Preferred Stock, each Preferred Stockholder, on behalf of itself and its successors,
assigns, Representatives (as defined in the Merger Agreement) and any other person or entity claiming by, through, or under any
of the foregoing, hereby unconditionally and irrevocably acquits, remises, discharges and forever releases the Company and its
Affiliates (as defined in the Merger Agreement) and its Representatives (as defined in the Merger Agreement) from any and all claims,
demands, damages, judgments, causes of action, liabilities and obligations of every kind whatsoever, whether accrued or fixed,
absolute or contingent, matured or unmatured or determined or determinable, arising out of or relating to each such Preferred Stockholder’s
ownership of the Preferred Shares (provided, that in the case of Blackwell, only to the extent arising out of or relating
to Blackwell’s ownership of Preferred Shares at any time that are subject to any investment management agreement between
Blackwell and Coliseum Capital Management, LLC as listed on Schedule 1). Notwithstanding the foregoing, the Preferred Stockholders
are not hereby releasing their rights with respect to (i) the 2015 Warrant Agreement and the Warrant Certificates issued thereunder
other than as otherwise set forth in this Agreement and with respect to any liabilities or obligations with respect to breaches
of any representations, warranties, or agreements therein arising prior to the Repurchase Closing and (ii) any rights or obligations
set forth in this Agreement. Each Preferred Stockholder hereby agrees that the contracts pursuant to which such Preferred Stockholder
obtained the Preferred Shares shall, effective as of the Repurchase Closing, be terminated in their entirety and no party thereto
shall have any further rights, duties, liabilities or obligations in connection therewith or arising thereunder.

 

    	 	5	 

     

    

 

12.             
Disclosure. The Company shall provide each Preferred Stockholder with a draft of any disclosure documents, filings
or press releases referencing, describing or filing this Agreement a reasonable period of time prior to the filing or publication
thereof, and shall consider in good faith any comments made by each Preferred Stockholder with respect thereto received within
twenty-four (24) hours after such drafts were delivered to the Preferred Stockholders.

 

13.             
Tax Treatment. For federal income tax purposes (and applicable state and local tax purposes), the parties acknowledge
and agree that the Repurchase is intended to be taxable exchange governed by Section 1001 of the Code. The parties will file all
tax returns in a manner consistent with such intent and shall not take an inconsistent position on any tax return or in any audit
or similar proceeding.

 

14.             
Governing Law; Venue. All terms of and rights under this Agreement shall be governed by and construed in accordance
with the laws of the State of Delaware, without giving effect to principles of conflicts of law. Each of the parties irrevocably
agrees that any legal action or proceeding arising out of or relating to this Agreement brought by any party against any other
party shall be brought and determined in the Court of Chancery of the State of Delaware; provided, however, that
if jurisdiction is not then available in the Court of Chancery of the State of Delaware, then any such legal action or proceeding
may be brought in any federal court located in the State of Delaware or any other Delaware state court. Each of the parties hereby
irrevocably submits to the jurisdiction of the aforesaid courts for itself and with respect to its property, generally and unconditionally,
with regard to any such action or proceeding arising out of or relating to this Agreement and the transactions contemplated hereby.
Each of the parties agrees not to commence any action, suit or proceeding relating thereto except in the courts described above
in Delaware, other than actions in any court of competent jurisdiction to enforce any judgment, decree or award rendered by any
such court in Delaware as described herein. Each of the parties further agrees that notice as provided herein shall constitute
sufficient service of process and the parties further waive any argument that such service is insufficient. Each of the parties
hereby irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise,
in any action or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby, (a) any
claim that it is not personally subject to the jurisdiction of the courts in Delaware as described herein for any reason, (b) that
it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether
through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise)
and (c) that (i) the suit, action or proceeding in any such court is brought in an inconvenient forum, (ii) the
venue of such suit, action or proceeding is improper or (iii) this Agreement, or the subject matter hereof, may not be enforced
in or by such courts.

 

    	 	6	 

     

    

 

15.             
Waiver of Jury Trial. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY THAT MAY ARISE PURSUANT TO THIS AGREEMENT
IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY
RIGHT THAT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL PROCEEDING (WHETHER FOR BREACH OF CONTRACT, TORTIOUS
CONDUCT OR OTHERWISE) DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.
EACH PARTY ACKNOWLEDGES AND AGREES THAT (i) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY
OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER; (ii) IT UNDERSTANDS
AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER; (iii) IT MAKES THIS WAIVER VOLUNTARILY; AND (iv) IT HAS BEEN INDUCED
TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 15.

 

16.             
Entire Agreement. This Agreement sets forth the entire agreement and understanding between the parties as to the
subject matter hereof and supersedes all prior oral and written and all contemporaneous oral discussions, agreements and understandings
of any kind or nature.

 

17.             
Severability. If any term of this Agreement is invalid, unlawful or incapable of being enforced by reason of any
rule of law or public policy, all other terms (or parts thereof) set forth herein which can be given effect without the invalid,
unlawful or unenforceable term will, nevertheless, remain in full force and effect, and no term herein (or parts thereof) set forth
will be deemed dependent upon any other such term unless so expressed herein.

 

18.             
Remedies. In the event of a breach by any party to this Agreement of its obligations under this Agreement, any party
injured by such breach, in addition to being entitled to exercise all rights granted by law, including recovery of damages, shall
be entitled to specific performance of its rights under this Agreement. The parties agree that the provisions of this Agreement
shall be specifically enforceable, it being agreed by the parties that the remedy at law, including monetary damages, for breach
of any such provision will be inadequate compensation for any loss and that any defense in any action for specific performance
that a remedy at law would be adequate is hereby waived.

 

    	 	7	 

     

    

 

19.             
Further Assurances. Each party shall cooperate and take such action as may be reasonably requested by another party
in order to carry out the provisions and purposes of this Agreement.

 

20.             
Assignment; Binding Effect. This Agreement shall not be assigned by operation of law or otherwise by any party hereto
without the prior written consent of the other parties hereto. This Agreement shall inure to the benefit of and be binding upon
the parties hereto and their respective permitted successors and assigns.

 

21.             
Amendment; Waiver. Any term of this Agreement may be amended and the observance of any such term may be waived (either
generally or in a particular instance) only with the prior written consent of the Company, Omega and each of the Preferred Stockholders.

 

22.             
Counterparts. This Agreement may be executed in two counterparts, each of which shall be deemed an original, but
which together shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Agreement
by facsimile shall be as effective as delivery of a manually executed counterpart to this Agreement.

 

23.             
Expenses. All fees and expenses incurred in connection herewith and the transactions contemplated hereby shall be
paid by the party incurring such expenses, whether or not the Mergers are consummated.

 

24.             
Third Party Beneficiary. The parties hereto acknowledge and agree that Omega is an express third party beneficiary
of this Agreement and shall have the right to enforce this agreement and rely upon the representations and warranties set forth
herein.

 

[The remainder of this
page has intentionally been left blank]

 

    	 	8	 

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Agreement with the intent that it be effective on the date first above written.

 

	 	BioScrip,
    Inc.
	 	 
	 	By:	 /s/
    Daniel Greenleaf
	 	 	Name:
    Daniel Greenleaf
	 	 	Title:
    President
	 	 	 
	 	 	 
	 	COLISEUM
    CAPITAL PARTNERS, L.P.
	 	 
	 	By:
    Coliseum Capital, LLC, its general partner
	 	 
	 	By:	/s/
    Christopher Shackelton
	 	 	Name:
    Christopher Shackelton
	 	 	Title:
    Manager
	 	 	 
	 	 	 
	 	COLISEUM
    CAPITAL PARTNERS II, L.P.
	 	 
	 	By:
    Coliseum Capital, LLC, its general partner
	 	 
	 	By:	/s/
    Christopher Shackelton
	 	 	Name:
    Christopher Shackelton
	 	 	Title:
    Manager
	 	 	 
	 	 	 
	 	BLACKWELL
    PARTNERS LLC – SERIES A
	 	 
	 	By:
    Coliseum Capital Management, LLC, Attorney-in-Fact
	 	 
	 	By:
    	/s/
    Christopher Shackelton
	 	 	Name:
    Christopher Shackelton
	 	 	Title:
    Managing Partner

 

 

     

     

    

 

SCHEDULE 1

 

 

	Name of Stockholder	 	 	Number of shares of Series C Preferred Stock
	COLISEUM CAPITAL PARTNERS, L.P.	 	 	386,655
	COLISEUM CAPITAL PARTNERS II, L.P.	 	 	86,520
	BLACKWELL PARTNERS LLC - SERIES A	 	 	141,002
	 	 	 	 
	Total:	 	 	614,177Exhibit 10.2

 

 

BIOSCRIP, INC.

__________________________

 

FORM OF AMENDED AND RESTATED WARRANT AGREEMENT

__________________________

 

Dated As Of March 14, 2019

Warrants to Purchase shares of Common Stock

 

BIOSCRIP, INC.

 

Amended and Restated Warrant Agreement

____________________________

 

Warrants For Common Stock

 

AMENDED AND RESTATED WARRANT AGREEMENT,
dated as March 14, 2019, among BioScrip, Inc., a Delaware corporation (together with its successors and assigns, the “Company”)
and the holders undersigned hereto (collectively and together with each of their respective successors and assigns, the “Holders”).
Capitalized terms shall have the meaning specified in Section 5.1 hereof.

RECITALS

 

WHEREAS, on the terms of the Warrant
Purchase Agreement (the “Original Warrant Agreement”), dated as June 29, 2017, among the Company and the Original
Purchasers party thereto, the Original Purchasers agreed to acquire from the Company, and the Company agreed to issue to the Original
Purchasers, Warrants to purchase 4.99% of the Fully Diluted Common Stock (as defined in the Original Warrant Agreement) outstanding
on the date of any exercise of the Warrants (less the percentage of the shares of Common Stock previously issued pursuant to the
Warrants from time to time as a result of any partial exercise of the Warrants as set forth herein);

 

WHEREAS, the Company is party to
an Agreement and Plan of Merger (the “Merger Agreement”), dated as of March 14, 2019, by and among the Company,
HC Group Holdings II, Inc., a Delaware corporation (“Omega”), Beta Sub, LLC, a Delaware limited liability company
(“Merger Sub LLC”), and certain other parties signatory thereto, pursuant to which Omega will be merged with
and into a newly formed subsidiary of the Company with Omega continuing as the surviving entity (the “Surviving Corporation”)
(the “First Merger”), immediately following which the Surviving Corporation will be merged with and into Merger
Sub LLC, with Merger Sub LLC continuing as the surviving entity (the “Second Merger”);

 

WHEREAS, the undersigned Holders
collectively own 100% of the Warrants issued pursuant to the Original Warrant Agreement;

 

WHEREAS, in connection with, and
conditioned upon, the consummation of the First Merger in accordance with the Merger Agreement, the Company and the Holders wish
to amend and restate the Original Warrant Agreement so as to fix the number of shares of Common Stock issuable upon exercise of
the Warrants at 8,287,317 shares in the aggregate, with each Holder having a Warrant to purchase the number of shares of Common
Stock set forth on Annex 1 hereto; and

 

WHEREAS, the Company and the Holders
wish to enter into this Agreement to amend and restate the terms of the Warrants.

 

AGREEMENT

 

NOW, THEREFORE, in consideration
of the premises and the mutual agreements set forth herein, the parties to this Agreement hereby agree to amend and restate the
Original Warrant Agreement as follows:

 

1. FORM,
EXECUTION AND TRANSFER OF WARRANT CERTIFICATES.

 

1.1 Form of Warrant Certificates.

 

The Warrant Certificates shall be in the
form set forth in Attachment A hereto. The Warrant Certificates may have such letters, numbers or other marks of identification
or designation as may be required to comply with any law or with any rule or regulation of any governmental authority, stock exchange
or self-regulatory organization made pursuant thereto (“Law”). Each Warrant Certificate shall be initially dated
as of June 29, 2017 and subsequently dated the date of issuance thereof by the Company upon transfer or exchange. Each Warrant
Certificate shall represent the right to purchase the number of shares of Common Stock set forth in such Warrant Certificate at
a price per share of Common Stock equal to the Exercise Price applicable to that Warrant Certificate; provided, that the
number of shares of Common Stock issuable upon exercise of the Warrants and the Exercise Price thereof shall be subject to adjustment
as provided herein. The aggregate amount of shares of Common Stock issuable upon exercise of all Warrants as of the Second Merger
Effective Time shall be 8,287,317, subject to adjustment as of the Second Merger Effective Time as provided herein, with each Holder
having a Warrant to purchase the number of shares of Common Stock set forth on Annex 1 hereto.

 

     

     

    

  

1.2 Execution of Warrant Certificates;
Registration Books.

 

(a) Execution of Warrant Certificates.
The Warrant Certificates shall be executed on behalf of the Company by an officer of the Company authorized by the Board of Directors.
In case the officer of the Company who shall have signed any Warrant Certificate shall cease to be such an officer of the Company
before issuance and delivery by the Company of such Warrant Certificate, such Warrant Certificate nevertheless may be issued and
delivered with the same force and effect as though the individual who signed such Warrant Certificate had not ceased to be such
an officer of the Company, and any Warrant Certificate may be signed on behalf of the Company by any individual who, at the actual
date of the execution of such Warrant Certificate, shall be a proper officer of the Company to sign such Warrant Certificate, although
at the date of the execution of this Agreement any such individual was not such an officer.

 

(b) Registration Books. The Company
will keep or cause to be kept at its office, maintained at the address of the Company referenced in Section 6.6, at the
Company’s transfer agent, or at such other office of the Company of which the Company shall have given notice to each holder
of Warrant Certificates, books for registration and transfer of the Warrant Certificates issued hereunder. Such books shall show
the names and addresses of the respective holders of the Warrant Certificates, the registration number and date of each of the
Warrant Certificates and the Denomination thereof.

 

1.3 Transfer, Split Up, Combination and
Exchange of Warrant Certificates; Lost or Stolen Warrant Certificates.

 

(a) Transfer, Split Up, etc.

 

(i) Transfer. Subject to compliance
with the Securities Act, any applicable state securities laws and the Company’s organizational documents, any Warrant Certificate
(or portion thereof), with or without other Warrant Certificates, may be transferred to any Person for a Warrant Certificate or
Warrant Certificates in an aggregate like Denomination as the Warrant Certificate or Warrant Certificates (or portions thereof)
surrendered then entitled such registered holder to purchase. Any registered holder desiring to transfer any Warrant Certificate
shall make such request in writing delivered to the Company, which request shall include the identity of the Transferee and the
aggregate Denomination of Warrants to be transferred, and shall surrender the Warrant Certificate or Warrant Certificates (or portions
thereof) to be transferred at the office of the Company referenced in Section 6.6, whereupon the Company shall deliver promptly
to such Transferee a Warrant Certificate or Warrant Certificates, as the case may be, as so requested, which Warrant Certificate
or Warrant Certificates shall evidence, collectively, the same aggregate Denomination of Warrants as the Warrant Certificate or
Warrant Certificates (or portions thereof) so surrendered for transfer and shall issue a new Warrant Certificate to the transferor
representing the Warrants retained by the Transferor if such transfer involved less than the entire Denomination of Warrants held
by such Transferor.

 

(ii) Split Up, Combination, Exchange,
etc. Any Warrant Certificate, with or without other Warrant Certificates, may be split up, combined or exchanged for another
Warrant Certificate or Warrant Certificates, in an aggregate like Denomination as the Warrant Certificate or Warrant Certificates
surrendered then entitle such registered holder to purchase. Any registered holder desiring to split up, combine or exchange any
Warrant Certificate shall make such request in writing delivered to the Company, and shall surrender the Warrant Certificate or
Warrant Certificates to be split up, combined or exchanged at the office of the Company referenced in Section 6.6, whereupon
the Company shall deliver promptly to such registered holder a Warrant Certificate or Warrant Certificates, as the case may be,
as so requested, which Warrant Certificate or Warrant Certificates shall evidence, collectively, the same aggregate Denomination
as the Warrant Certificate or Warrant Certificates so surrendered for split-up, combination or exchange.

 

(b) Loss, Theft, etc. Upon receipt
by the Company of evidence reasonably satisfactory to it of the ownership of, and the loss, theft, destruction or mutilation of,
any Warrant Certificate, and:

 

(i) in the case of loss, theft or destruction,
an affidavit of loss, together with a customary and reasonable indemnity reasonably satisfactory to the Company; or

 

(ii) in the case of mutilation, upon surrender
and cancellation thereof;

 

the Company at its own expense will execute
and deliver, in lieu thereof, a new Warrant Certificate, dated the date of such lost, stolen, destroyed or mutilated Warrant Certificate
and of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant Certificate and evidencing the same Denomination
as the Warrant Certificate so lost, stolen, destroyed or mutilated.

 

     

     

    

 

1.4 Subsequent Issuance of Warrant Certificates.

 

Subsequent to the original issuance, no
Warrant Certificates shall be issued except:

 

(a) Warrant Certificates issued upon any transfer,
combination, split up or exchange of Warrants pursuant to Section 1.3(a);

 

(b) Warrant Certificates issued in replacement
of mutilated, destroyed, lost or stolen Warrant Certificates pursuant to Section 1.3(b);

 

(c) Warrant Certificates issued pursuant to
Section 2.3 upon the partial exercise of any Warrant Certificate to evidence the unexercised portion of such Warrant Certificate;
and

 

(d) Warrant Certificates to reflect any adjustments
pursuant to Section 4.

 

1.5 Effect of Issuance in Registered
Form.

 

Every holder of a Warrant Certificate by
accepting the same consents and agrees with the Company and with every other holder of a Warrant Certificate that:

 

(a) the Warrant Certificates, to the extent
then currently transferable, are transferable only on the registry books of the Company if and when surrendered at the office of
the Company referenced in Section 6.5, duly endorsed or accompanied by an instrument of transfer (in the form attached thereto)
and payment of any applicable transfer, stamp or issue tax (a “Tax”); and

 

(b) the Company may deem and treat the Person
in whose name each Warrant Certificate is registered as the absolute owner thereof and of the Warrants evidenced thereby (notwithstanding
any notations of ownership or writing on the Warrant Certificates made by anyone other than the Company) for all purposes whatsoever,
and the Company shall not be affected by any notice to the contrary.

 

2. EXERCISE
OF WARRANTS; PAYMENT OF EXERCISE PRICE.

 

2.1 Exercise of Warrants.

 

(a) Manner of Exercise. At any time
and from time to time prior to the Expiration Time, the holder of any Warrant Certificate may exercise the Warrants evidenced thereby,
in whole or in any part, by surrender to the Company, at its office referenced in Section 6.6, of such Warrant Certificate,
together with a duly executed election to purchase (a form of which is attached to each Warrant Certificate) and payment of the
applicable Exercise Price for each share of Common Stock with respect to which the Warrants are then being exercised and an amount
equal to any applicable Tax (if not payable by the Company as provided in Section 3.3). Such Exercise Price shall be payable
in cash or by withholding of shares of Common Stock into which the Warrants are being exercised pursuant to Section 2.1(b).

 

(b) Payment in Cash or by Withholding of
Common Stock. Upon exercise of any Warrants, the holder of a Warrant Certificate may pay the Exercise Price by either (i) certified
or official bank check payable to the order of the Company or by wire transfer of immediately available funds to the account of
the Company designated in writing by the Company or (ii) instructing the Company to withhold that number of shares of Common Stock
(or fraction thereof) then issuable upon such exercise with an aggregate Market Price as of such exercise date equal to the aggregate
Exercise Price. The Company acknowledges that the provisions of this clause are intended, in part, to ensure that a full or partial
exchange of a Warrant Certificate will qualify as a conversion, within the meaning of paragraph (d)(3)(ii) of Rule 144 under the
Securities Act.

 

(c) Fractional shares of Common Stock.
The Company may, in accordance with Section 2.6, pay the exercising holder cash in lieu of issuing a fractional share in
connection with an exercise of Warrants; provided that, if it does not issue a fractional share in such circumstances, it will
make such cash payment.

 

2.2 Issuance of Common Stock.

 

Upon timely receipt of a Warrant Certificate,
accompanied by the form of election to purchase duly executed, and payment of the Exercise Price for each of the shares of the
Common Stock to be purchased and by an amount equal to any applicable Tax (if not payable by the Company as provided in Section
3.3), the Company shall thereupon promptly cause certificates representing the number of whole shares of Common Stock then
being purchased to be delivered to or upon the order of the registered holder of such Warrant Certificate, registered in such name
or names as may be designated by such holder, and, promptly after such receipt deliver the cash, if any, to be paid in lieu of
fractional shares pursuant to Section 2.6 to or upon the order of the registered holder of such Warrant Certificate.

 

     

     

    

 

2.3 Unexercised Warrants.

 

In the event that the registered holder
of any Warrant Certificate shall exercise less than all the Warrants evidenced thereby, a new Warrant Certificate evidencing a
number of unexercised Warrants shall be issued by the Company to the registered holder of such Warrant Certificate or to its duly
authorized assigns.

 

2.4 Cancellation and Destruction of Warrant
Certificates.

 

All Warrant Certificates surrendered to
the Company for the purpose of exercise, payment of the Exercise Price, exchange, substitution or transfer shall be cancelled by
it, and no Warrant Certificates shall be issued in lieu thereof except as expressly permitted by any of the provisions of this
Agreement. The Company shall cancel and retire any other Warrant Certificates purchased or acquired by the Company.

 

2.5 Expiration.

 

All Warrants that have not been exercised
or purchased in accordance with the provisions of this Agreement shall expire and all rights of holders of such Warrants hereunder
shall terminate and cease at the Expiration Time.

 

2.6 Fractional shares of Common Stock.

 

The Company shall not be required to issue
fractional shares of Common Stock upon the exercise of any Warrant. If fractional shares are not issued upon the exercise of any
Warrant, there shall be paid to the holder thereof, in lieu of any fractional share of Common Stock resulting therefrom, an amount
of cash equal to the product of:

 

(a) the fractional amount of such share of
Common Stock; and

 

(b) the Market Price, as determined on the
trading day immediately prior to the date of exercise of such Warrant.

 

2.7 RESERVED

 

3. AGREEMENTS
OF THE COMPANY.

 

3.1 Reservation of Common Stock.

 

The Company covenants and agrees that it
will at all times cause to be reserved and kept available out of its authorized and unissued shares of treasury shares of Common
Stock such number of shares of Common Stock as will be sufficient to permit the exercise in full of all Warrants issued hereunder
into Common Stock.

 

3.2 Common Stock to be Duly Authorized
and Issued, Fully Paid and Nonassessable, etc; Compliance with Law

 

The Company covenants and agrees that it
will take all such action as may be necessary to ensure that all shares of Common Stock delivered upon the exercise of any Warrant
and the payment of the Exercise Price pursuant to Section 2.1 (in each case, at the time of delivery of the certificates
representing such shares of Common Stock) shall (a) be duly and validly authorized and issued and fully paid and nonassessable,
free of any preemptive rights in favor of any Person in respect of such issuance and free of any security interest, pledge, mortgage,
lien, charge or other encumbrance created by, or arising out of actions of, the Company, in each case other than (i) resulting
from the actions and circumstances of the holder of such shares of Common Stock, (ii) to the extent imposed by applicable laws
or (iii) in the Company’s organizational documents and (b) be issued without violation of any applicable Law.

 

3.3 Taxes.

 

The Company covenants and agrees that it
will pay when due and payable any and all Taxes and charges that may be payable in respect of the initial issuance or delivery
of:

 

(a) each Warrant Certificate;

 

(b) each Warrant Certificate issued in exchange
for any other Warrant Certificate pursuant to Section 1.3, Section 2.3 or Section 4; and

 

(c) each share of Common Stock issued upon
the exercise of any Warrant.

 

     

     

    

 

The Company shall not, however, be required
to:

 

(i) pay any Tax that may be payable in respect
of the transfer or delivery of Warrant Certificates in a name other than that of the registered holder of the Warrant Certificate
surrendered for exercise, conversion, transfer or exchange (any such Tax being payable by the holder of such certificate at the
time of surrender); or

 

(ii) issue or deliver any such certificates
referred to in the foregoing clause (i) until any such Tax referred to in the foregoing clause (i) shall have been paid.

 

3.4 Common Stock Record Date.

 

Each Person in whose name any certificate
for shares of Common Stock is issued upon the exercise of Warrants shall for all purposes be deemed to have become the holder of
record of the Common Stock represented thereby on, and such certificates (if any) shall be dated, the date upon which the Warrant
Certificate evidencing such Warrants was duly surrendered with an election to purchase attached thereto duly executed and payment
of the aggregate Exercise Price (and any applicable Taxes, if payable by such Person) was made.

 

3.5 Rights in Respect of Common Stock.

 

Prior to the exercise of the Warrants evidenced
thereby, the holder of a Warrant Certificate shall not be entitled to any rights of a stockholder of the Company with respect to
the Common Stock into which the Warrants shall be exercisable, including, without limitation, the right to vote in respect of any
matter upon which the holders of Common Stock may vote, the right to receive any distributions of cash or property and, except
as expressly set forth herein, the right to receive any notice of any proceedings of the Company. Prior to the exercise of the
Warrants evidenced thereby, the holders of the Warrant Certificates shall not have as such any obligation in respect of any assessment
or any other obligation or liability as a stockholder of the Company, whether such obligations or liabilities are asserted by the
Company or by creditors of the Company.

 

3.6 Noncircumvention.

 

The Company hereby covenants and agrees
that the Company will not, by amendment of its charter, bylaws or through any reorganization, transfer of assets, consolidation,
merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid
the observance or performance of any of the terms of this Warrant Agreement, and will at all times in good faith carry out all
the provisions of this Warrant Agreement.

 

4. ANTI-DILUTION
ADJUSTMENTS.

 

4.1 Adjustments.

 

The number of shares of Common Stock purchasable
upon the exercise of each Warrant, and the Exercise Price, shall be subject to adjustment as set forth in this Section 4;
provided that no adjustment of the Exercise Price shall result in an increase in the Exercise Price.

 

4.2 Stock Splits, Subdivisions, Reclassifications
or Combinations.

 

If the Company shall (i) declare and pay
a dividend or make a distribution on its Common Stock in shares of Common Stock, (ii) subdivide or reclassify the outstanding shares
of Common Stock into a greater number of shares, or (iii) combine or reclassify the outstanding shares of Common Stock into a smaller
number of shares, the Denomination of any Warrant Certificate and the Common Stock issuable upon exercise of any Warrants at the
time of the record date for such dividend or effective date of such split, reverse split, subdivision, combination or reclassification
shall be proportionately adjusted so that the holder of such Warrants after such date shall be entitled to purchase the number
of shares of Common Stock which such holder would have owned or been entitled to receive in respect of the shares of Common Stock
subject to such Warrants after such date had such Warrants been exercised immediately prior to such date. In such event the Exercise
Price in effect at the time of the effective date of such split, reverse split, subdivision, combination or reclassification shall
be adjusted to the number obtained by dividing (x) the product of (1) the number of shares of Common Stock issuable upon the exercise
of such Warrants immediately before such adjustment and (2) the Exercise Price in effect immediately prior to the record or effective
date, as the case may be, for the dividend, distribution, split, reverse split, subdivision, combination or reclassification giving
rise to this adjustment by (y) the new number of shares of Common Stock issuable upon exercise of such Warrants determined pursuant
to the immediately preceding sentence; provided that the Exercise Price shall not be adjusted to be less than the par value of
the Common Stock; provided, further, that the adjustment to the Exercise Price in this Section 4.2 may result in an increase
in the Exercise Price, notwithstanding Section 4.1.

 

     

     

    

 

4.3 Price Based Anti-Dilution

 

(a) Without duplication of the adjustments
set forth in Sections 4.2 or 4.4, if the Company shall issue after the Second Merger Effective Time or sell any shares
of Common Stock (as actually issued or, pursuant to Section 4.3(b), deemed to be issued) for a consideration per share less
than either the Market Price per share or the Exercise Price immediately prior to such issuance or sale, or if earlier, upon the
execution of the definitive documentation with respect to such issuance or sale (the “Effective Time”), then
immediately upon the Effective Time the Denomination of any Warrant Certificate and the number of shares of Common Stock issuable
upon exercise of any Warrants at the time of the effective date shall be increased by multiplying such number of shares of Common
Stock by a fraction, (i) the numerator of which shall be the number of shares of Common Stock actually outstanding immediately
prior to the Effective Time plus the number of shares of Common Stock so issued or sold (or deemed to be issued or sold pursuant
to Section 4.3(b)), and (ii) the denominator of which shall be the number of shares of Common Stock actually outstanding immediately
prior to the Effective Time plus the number of shares of Common Stock which the aggregate consideration received by the Company
for the total number of shares of Common Stock so issued or sold (or deemed to be issued or sold pursuant to Section 4.3(b)) would
purchase if such shares were sold at the greater of the Market Price or the Exercise Price, and the Exercise Price shall be adjusted
by multiplying the Exercise Price in effect immediately prior to such issuance or sale (or deemed issuance or sale) by the inverse
of such fraction. For the purposes of this Section 4.3(a), none of the following issuances shall be considered the issuance
or sale of Common Stock:

 

(i) the issuance of Common Stock (a) upon
the conversion or exercise of any then-outstanding Common Stock Equivalents; (b) to Persons in connection with joint ventures,
strategic alliances or other commercial relationships with such Person relating to the operation of the Company’s business
and not for the primary purpose of raising equity capital, in connection with Business Combinations, or transactions in which the
Company, directly or indirectly, acquires another business or the assets thereof or (c) in an offering for cash for account of
the Company that is underwritten on a firm commitment basis and is registered with the Securities and Exchange Commission;

 

(ii) the issuance of any Common Stock or
Common Stock Equivalents for which the adjustment provided in Section 4.2 applies; or

 

(iii) the issuance of shares of Common Stock
or Common Stock Equivalents to employees or directors of either the Company or any Company Subsidiary that is approved by the Board
of Directors.

 

(b) For the purposes of Section 4.3(a),
the following subparagraphs (i) to (iii), inclusive, shall also be applicable:

 

(i) If the Company shall grant any rights
to subscribe for, or any rights or options to purchase, Common Stock Equivalents, whether or not such rights or options or the
right to convert or exchange any such Common Stock Equivalents are immediately exercisable, and the price per share for which Common
Stock is issuable upon the exercise of such rights or options or upon conversion or exchange of such Common Stock Equivalents (determined
by dividing (A) the total amount, if any, received or receivable by the Company as consideration for the granting of such rights
or options, plus the minimum aggregate amount of additional consideration payable to the Company upon the exercise of such rights
or options, plus, in the case of any such rights or options which relate to such Common Stock Equivalents, the minimum aggregate
amount of additional consideration, if any, payable upon the issue or sale of such Common Stock Equivalents and upon the conversion
or exchange thereof, by (B) the total maximum number of shares of Common Stock issuable upon the exercise of such rights or options
or upon the conversion or exchange of all such Common Stock Equivalents issuable upon the exercise of such rights or options) shall
be less than the Exercise Price or the Market Price per share of Common Stock immediately prior to the earlier of (x) the time
of the granting of such rights or options and (y) the time of execution of definitive documentation with respect to such grant
(such earlier time of (x) and (y) to be the “Effective Time” for purposes of Section 4.3(a)), then the
total maximum number of shares of Common Stock issuable upon the exercise of such rights or options or upon conversion or exchange
of the total maximum amount of such Common Stock Equivalents issuable upon the exercise of such rights or options shall (as of
the date of granting of such rights or options or the date of execution of definitive documents, if earlier) be deemed to be outstanding
and to have been issued for such price per share; provided that no further adjustment of the conversion price pursuant to this
Section 4.3(a) or Section 4.3(b)(i) shall be made (x) upon the actual issuance or sale of such Common Stock Equivalents
upon the exercise of any rights to subscribe for, or any rights or options to purchase, such Common Stock Equivalents or (y) upon
the actual issuance or sale of such Common Stock upon the exercise of any such Common Stock Equivalents, including without limitation,
in each case of clauses (x) and (y) with respect to shares of Common Stock Equivalents or Common Stock issued or issuable as a
result of the effect of antidilution adjustments under any such security.

 

(ii) If the Company shall issue or sell
any Common Stock Equivalents, whether or not the rights to exchange or convert thereunder are immediately exercisable, and the
price per share for which Common Stock is issuable upon such conversion or exchange (determined by dividing (A) the total amount
received or receivable by the Company as consideration for the issue or sale of such Common Stock Equivalents, plus the minimum
aggregate amount of additional consideration, if any, payable to the Company upon the conversion or exchange thereof, by (B) the
total maximum number of shares of Common Stock issuable upon the conversion or exchange of all such Common Stock Equivalents) shall
be less than the Exercise Price or the Market Price per share of Common Stock immediately prior to the Effective Time for such
issuance or sale, then the total maximum number of shares of Common Stock issuable upon conversion or exchange of such Common Stock
Equivalents shall (as of the Effective Time) be deemed to be outstanding and to have been issued for such price per share, provided
that no further adjustment of the conversion price pursuant to this Section 4.3(a) or Section 4.3(b)(ii) shall be
made upon the actual issuance or sale of such Common Stock upon the exercise of any such Common Stock Equivalents, including without
limitation, in each case with respect to shares of Common Stock issued or issuable as a result of the effect of antidilution adjustments
under any such security.

 

     

     

    

 

(iii) In case at any time any shares of
Common Stock or Common Stock Equivalents or any rights or options to purchase any such Common Stock or Common Stock Equivalents
shall be issued or sold for cash to a non-Affiliate of the Company, the consideration received therefor shall be deemed to be the
amount received by the Company therefor. In case any shares of Common Stock or Common Stock Equivalents or any rights or options
to purchase any such Common Stock or Common Stock Equivalents shall be issued or sold to an Affiliate of the Company or for a consideration
other than or in addition to cash, the amount of the consideration received by the Company shall be deemed to be the Fair Market
Value of solely such consideration received by the Company in respect of such purchase of Common Stock or Common Stock Equivalents.

 

4.4 Other Distributions. In case
the Company shall fix a record date for the making of a dividend or distribution to holders of shares of its Common Stock of securities,
evidences of indebtedness, assets, cash, rights or warrants (excluding dividends of its Common Stock and other dividends or distributions
referred to in Section 4.2), in each such case, the Exercise Price in effect prior to such record date shall be reduced immediately
thereafter to the price determined by multiplying the Exercise Price in effect immediately prior to the reduction by the quotient
of (x) the Market Price of the Common Stock on the last trading day preceding the first date on which the Common Stock trades on
the Exchange on which the Common Stock is listed or admitted to trading without the right to receive such distribution, minus the
amount of cash and/or the Fair Market Value of the securities, evidences of indebtedness, assets, rights or warrants to be so distributed
in respect of one share of Common Stock (such amount and/or Fair Market Value, the “Per Share Fair Market Value”) divided
by (y) such Market Price on such date specified in clause (x); such adjustment shall be made successively whenever such a record
date is fixed. In such event, the Denomination of any Warrant Certificate and the Common Stock issuable upon the exercise of any
Warrants shall be increased to the number obtained by dividing (x) the product of (1) the number of shares of Common Stock issuable
upon the exercise of such Warrants before such adjustment, and (2) the Exercise Price in effect immediately prior to the distribution
giving rise to this adjustment by (y) the new Exercise Price determined in accordance with the immediately preceding sentence.
In the event that such distribution is not so made, the Exercise Price and the number of shares of Common Stock issuable upon exercise
of such Warrants then in effect shall be readjusted, effective as of the date when the Board of Directors determines not to distribute
such shares, evidences of indebtedness, assets, rights, cash or warrants, as the case may be, to the Exercise Price that would
then be in effect and the number of shares of Common Stock that would then be issuable upon exercise of such Warrants if such record
date had not been fixed.

 

4.5 Business Combinations.

 

In case of any Business Combination or reclassification
of Common Stock (other than a reclassification of Common Stock referred to in Section 4.2), a holder’s right to receive
shares of Common Stock upon exercise of any Warrants shall be converted into the right to exercise such Warrant to acquire the
number of shares of stock or other securities or property (including cash) which the Common Stock issuable (at the time of such
Business Combination or reclassification) upon exercise of such Warrants immediately prior to such Business Combination or reclassification
would have been entitled to receive upon consummation of such Business Combination or reclassification; and in any such case, if
necessary, the provisions set forth herein with respect to the rights and interests thereafter of such holder shall be appropriately
adjusted so as to be applicable, as nearly as may reasonably be, to such holder’s right to exercise such Warrants in exchange
for any shares of stock or other securities or property pursuant to this Section 4.5. In determining the kind and amount
of stock, securities or the property receivable upon exercise of any Warrants following the consummation of such Business Combination,
if the holders of Common Stock have the right to elect the kind or amount of consideration receivable upon consummation of such
Business Combination, then the holder of such Warrants shall be entitled to elect the kind or amount of consideration receivable
upon consummation of such Business Combination. The Company shall not enter into or be party to any Business Combination unless
the successor of the Company (if any), assumes in writing the obligation to deliver to each holder of Warrants hereunder in exchange
for such Warrants a security of such successor evidenced by a written instrument substantially similar in form and substance to
this Agreement.

 

4.6 Expiration of Rights or Options.

 

Upon the expiration of any rights or options
to subscribe for, purchase or convert or exchange Common Stock or Common Stock Equivalents in respect of the issuance, sale or
grant of which adjustment was made pursuant to Section 4.3, without the exercise thereof, the Exercise Price and the number
of shares of Common Stock purchasable upon the exercise of the Warrants shall, upon such expiration, be readjusted (and such readjustment
may result in an increase in the Exercise Price, notwithstanding Section 4.1, not to exceed the Exercise Price prior to
such original adjustment) and shall thereafter be such Exercise Price and such number of shares of Common Stock as would have been
in effect had such Exercise Price and such number of shares of Common Stock not been originally adjusted (or had the original adjustment
not been required, as the case may be), as if:

 

     

     

    

 

(a) the only shares of Common Stock so issued
were the shares of Common Stock, if any, actually issued or sold upon the exercise of such rights or options; and

 

(b) such shares of Common Stock, if any, were
issued or sold for the consideration actually received by the Company upon such exercise plus the aggregate consideration, if any,
actually received by the Company for the issuance, sale or grant of all of such rights or options, whether or not exercised; provided
that no such readjustment shall have the effect of increasing the Exercise Price by an amount in excess of the amount of the reduction
initially made in respect of the issuance, sale, or grant of such rights or options.

 

4.7 Rounding of Calculations; Minimum
Adjustments.

 

All calculations under this Section 4
shall be made to the nearest one-tenth (1/10th) of a cent or to the nearest one-hundredth (1/100th) of a share, as the case may
be. Any provision of this Section 4 to the contrary notwithstanding, no adjustment in the Exercise Price or the number of
shares of Common Stock into which any Warrants are exercisable shall be made if the amount of such adjustment would be less than
$0.01 or one-tenth (1/10th) of a share of Common Stock, but any such amount shall be carried forward and an adjustment with respect
thereto shall be made at the earlier of (i) the time of any exercise of Warrants and (ii) the time of and together with any subsequent
adjustment which, together with such amount and any other amount or amounts so carried forward, shall aggregate $0.01 or 1/10th
of a share of Common Stock, or more.

 

4.8 Timing of Issuance of Additional
Common Stock Upon Certain Adjustments.

 

In any case in which the provisions of this
Section 4 shall require that an adjustment shall become effective immediately after a record date for an event, the Company
may defer until the occurrence of such event (i) issuing to the holder of any Warrants exercised after such record date and before
the occurrence of such event the additional shares of Common Stock issuable upon such exercise by reason of the adjustment required
by such event over and above the shares of Common Stock issuable upon such exercise before giving effect to such adjustment and
(ii) paying to such holder any amount of cash in lieu of a fractional share of Common Stock; provided, however, that the
Company upon written request shall deliver to such holder a due bill or other appropriate instrument evidencing such holder’s
right to receive such additional shares, and such cash, upon the occurrence of the event requiring such adjustment.

 

4.9 Miscellaneous.

 

(a) Statement Regarding Adjustments.
Whenever after the Second Merger Effective Time the Exercise Price or the number of shares of Common Stock into which any Warrants
are exercisable shall be adjusted as provided in Section 4, the Company shall promptly file at the principal office of the
Company referenced in Section 6.6 a statement showing in reasonable detail the facts requiring such adjustment and the Exercise
Price that shall be in effect and the number of shares of Common Stock into which such Warrants shall be exercisable after such
adjustment, and the Company shall also cause a copy of such statement to be sent by mail, first class postage prepaid, or email
to each holder of Warrants at the address or email address appearing in the Company’s records.

 

(b) Notice of Adjustment Event. In
the event that the Company shall propose after the Second Merger Effective Time to take any action of the type described in this
Section 4 (but only if the action of the type described in this Section 4 would result in an adjustment in the Exercise
Price or the number of shares of Common Stock into which Warrants are exercisable or a change in the type of securities or property
to be delivered upon exercise of Warrants), the Company shall give notice to the holders of Warrants, in the manner set forth in
Section 4.9(a), which notice shall specify the record date, if any, with respect to any such action and the approximate
date on which such action is to take place. Such notice shall also set forth the facts with respect thereto as shall be reasonably
necessary to indicate the effect on the Exercise Price and the number, kind or class of shares or other securities or property
which shall be deliverable upon exercise of any Warrants. In the case of any action which would require the fixing of a record
date, such notice shall be given at least 10 days prior to the date so fixed, and in case of all other action, such notice shall
be given at least 15 days prior to the taking of such proposed action. Without limiting the foregoing, to the extent notice of
any of the foregoing actions or events is given to the holders of the Common Stock, such notice shall be provided to the holders
of the Warrants on or before such notice to the holders of Common Stock.

 

(c) Proceedings Prior to Any Action Requiring
Adjustment. As a condition precedent to the taking of any action which would require an adjustment pursuant to this Section
4, the Company shall take any action which may be necessary, including obtaining regulatory, New York Stock Exchange, NASDAQ Stock
Market or other applicable national securities exchange (an “Exchange”) or stockholder approvals or exemptions, in
order that the Company may thereafter validly and legally issue as fully paid and nonassessable all shares of Common Stock that
the holders are entitled to receive upon exercise of this any Warrants pursuant to this Section 4.

 

     

     

    

 

(d) Adjustment Rules. Any adjustments
pursuant to this Section 4 shall be made successively whenever an event referred to herein shall occur. If more than one
subsection of this Section 4 is applicable to a single event, the subsection shall be applied that produces the largest
adjustment and no single event shall cause an adjustment under more than one subsection of this Section 4 so as to result
in duplication. If an adjustment in Exercise Price made hereunder would reduce the Exercise Price to an amount below par value
of the Common Stock, then such adjustment in Exercise Price made hereunder shall reduce the Exercise Price to the par value of
the Common Stock.

 

(e) Merger Agreement. Notwithstanding
anything contained herein to the contrary, the consummation of the transactions contemplated by the Merger Agreement (including
the issuance of any shares of Common Stock by the Company contemplated therein) will not result in, or cause any adjustment in,
the Exercise Price or the number of shares of Common Stock into which any Warrants are exercisable pursuant to this Section
4.

 

5. INTERPRETATION
OF THIS AGREEMENT.

 

5.1 Certain Defined Terms.

 

For the purpose of this Agreement, the following
terms shall have the meanings set forth below or set forth in the Section hereof following such term:

 

“Affiliate” means, with
respect to any Person, (a) a director, officer or shareholder of such Person, (b) in the case of a natural person, a spouse, parent,
sibling or descendant of such Person (or spouse, parent, sibling or descendant of any director or executive officer of such Person)
and (c) any other Person that, directly or indirectly through one or more intermediaries, Controls, or is Controlled by, or is
under common Control with, such Person, at such time; provided, however, that none of the Holders shall be deemed to be an “Affiliate”
of the Company and no Person holding any one or more of the Warrants shall be deemed to be an “Affiliate” of the Company
solely by virtue of the ownership thereof.

 

“Agreement” means this
Amended and Restated Warrant Agreement as it may from time to time be amended, restated, modified or supplemented.

 

“Board of Directors”
means the board of directors of the Company, including any duly authorized committee thereof.

 

“Beneficially Own” has
the meaning has the meaning given to it in Section 13D of the Exchange Act and the rules promulgated thereunder.

 

“Business Combination”
means any consolidation of the Company with, or merger of the Company with or into, another Person (other than a merger in which
(a) the Company is the surviving corporation, (b) that does not result in any reclassification or change of shares of Common Stock
outstanding immediately prior to such merger and (c) the holders of Common Stock are not entitled to receive any consideration
therefrom), or any sale or conveyance to another Person of the assets of the Company substantially as an entirety.

 

“business day” means
any day that is not a Saturday, Sunday or other day on which banking institutions in New York, New York are authorized or required
by Law or executive order to close.

 

“Capital Stock” means
(A) with respect to any Person that is a corporation or company, any and all shares, interests, participations or other equivalents
(however designated) of capital or capital stock of such Person and (B) with respect to any Person that is not a corporation or
company, any and all partnership or other equity interests of such Person.

 

“Charter” means, with
respect to any Person, its certificate or articles of incorporation, articles of association, or similar organizational document.

 

“Common Stock” means
the Company’s common stock, par value $.0001 per share.

 

“Common Stock Equivalents”
means all options, derivatives, rights, warrants and convertible, exercisable or exchangeable securities or instruments (including,
without limitation, awards or grants of such securities or instruments to directors, officers, employees or consultants of the
Company or to other persons).

 

“Company” has the meaning
set forth in the introductory paragraph hereof.

 

“Control” means, with
respect to any Person, the possession, directly or indirectly, of the power to direct or cause the direction of the management
and policies of such Person, whether through the ownership of voting Securities, by contract or otherwise.

 

     

     

    

 

“Denomination” means,
in the case of any Warrant Certificate, the number of shares of Common Stock issuable upon exercise of the Warrants represented
by such Warrant Certificate.

 

“Effective Date” shall
mean the date on which the Second Merger is consummated in accordance with the terms of the Merger Agreement.

 

“Effective Time” has
the meaning set forth in Section 4.3(a).

 

“Exchange” has the set
forth in Section 4.9(c).

 

“Exchange Act” means
the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations promulgated thereunder.

 

“Exercise Price” means,
prior to any adjustment pursuant to Section 4 of this Agreement, the Initial Exercise Price; and thereafter, the Initial
Exercise Price as successively adjusted and readjusted from time to time in accordance with the provisions of Section 4.

 

“Expiration Time” means
5:00 p.m., Eastern time, on the tenth (10th) year anniversary of June 29, 2017.

 

“Fair Market Value” means,
with respect to any security or other property, the fair market value of such security or other property as determined by the Board
of Directors, acting in good faith and transmitted to the holders of Warrants by written notice. The Required Warrantholders may
object in writing to the Board of Director’s calculation of Fair Market Value within 10 days of receipt of such written notice
thereof. If the Required Warrantholders and the Board of Directors are unable to agree on Fair Market Value during the 10-day period
following the delivery of the Required Warrantholders’ objection, then the Board of Directors shall select and approve an
appraiser of national recognition experienced in the business of evaluating or appraising the market value of securities (which
appraiser shall be subject to approval by the Required Warrantholders, which approval shall not be unreasonably withheld, conditioned
or delayed). The Fair Market Value established by such appraiser shall be conclusive and binding on the parties. The fees and expenses
for such appraiser shall be borne 50% by the Company, on the one hand, and 50% by the holders of Warrants, on the other hand.

 

“Initial Exercise Price”
means, with respect to each Warrant Certificate issued to a Holder on the Issue Date, $2.00.

 

“Issue Date” means June
29, 2017.

 

“Law” has the set forth
in Section 1.1.

 

“Market Price” means,
with respect to a particular security, on any given day, the volume weighted average trading price for the period of ten consecutive
trading days ending on the trading day prior to such given day as reported by Bloomberg Financial Markets, or any successor thereto,
through its “Volume Weight Average Price” function, on the Exchange on which the applicable securities are listed or
admitted to trading. “Market Price” shall be determined without reference to after hours or extended hours trading.
If such security is not listed and traded in a manner that the quotations referred to above are available for the period required
hereunder, the Market Price per share of Common Stock shall be deemed to be the fair market value per share of such security as
determined in good faith by the Board of Directors in reliance on an opinion of a nationally recognized independent investment
banking corporation retained by the Company for this purpose (which opinion shall be made available to the holders of Warrants);
provided that the Required Warrantholders may object in writing to the Board of Director’s calculation of fair market value
within 10 days of receipt of written notice thereof. If the Required Warrantholders and the Board of Directors are unable to agree
on fair market value during the 10-day period following the delivery of the Required Warrantholders’ objection, then the
Board of Directors shall select and approve an appraiser experienced in the business of evaluating or appraising the market value
of securities (which appraiser shall be subject to approval by the Required Warrantholders, which approval shall not be unreasonably
withheld, conditioned or delayed). The Market Price established by such appraiser shall be conclusive and binding on the parties.
In the event the Market Price established by such appraiser is greater than the Market Price previously determined by the Board
of Directors, the fees and expenses for such appraiser shall be borne by the Company. In the event the Market Price established
by such appraiser is less than or equal to the Market Price previously determined by the Board of Directors, the fees and expenses
for such appraiser shall be borne by the holders of Warrants. For the purposes of determining the Market Price of the Common Stock
on the “trading day” preceding, on or following the occurrence of an event, (i) that trading day shall be deemed to
commence immediately after the regular scheduled closing time of trading on the Nasdaq Stock Market or, if trading is closed at
an earlier time, such earlier time and (ii) that trading day shall end at the next regular scheduled closing time, or if trading
is closed at an earlier time, such earlier time (for the avoidance of doubt, and as an example, if the Market Price is to be determined
as of the last trading day preceding a specified event and the closing time of trading on a particular day is 4:00 p.m. and the
specified event occurs at 5:00 p.m. on that day, the Market Price would be determined by reference to such 4:00 p.m. closing price).

 

     

     

    

 

“Original Warrant Agreement”
has the meaning set forth in the recitals hereto.

 

“Per Share Fair Market Value”
has the meaning set forth in Section 4.4.

 

“Person” has the meaning
given to it in Section 3(a)(9) of the Exchange Act and as used in Sections 13(d)(3) and 14(d)(2) of the Exchange Act.

 

“Holders” has the meaning
set forth in the introductory paragraph hereof.

 

“Required Warrantholders”
means, at any time, the holders of Warrants representing at least a majority of the Common Stock issuable upon exercise of the
Warrants issued and outstanding hereunder and not previously exercised (exclusive of any Warrants directly or indirectly held by
the Company or any Affiliate of the Company).

 

“Securities Act” means
the Securities Act of 1933, as amended, or any successor statute, and the rules and regulations promulgated thereunder.

 

“Tax” or “Taxes”
has the meaning set forth in Section 1.5(a).

 

“trading day” means (A)
if the shares of Common Stock are not traded on any national or regional securities exchange or association or over-the-counter
market, a business day or (B) if the shares of Common Stock are traded on any national or regional securities exchange or association
or over-the-counter market, a business day on which such relevant exchange or quotation system is scheduled to be open for business
and on which the shares of Common Stock (i) are not suspended from trading on any national or regional securities exchange or association
or over-the-counter market for any period or periods aggregating one half hour or longer; and (ii) have traded at least once on
the national or regional securities exchange or association or over-the-counter market that is the primary market for the trading
of the shares of Common Stock.

 

“Transferee” means any
registered transferee of all or any part of any one or more Warrant Certificates initially acquired by the Holders under this Agreement.

 

“Warrant” means a warrant
to initially purchase one share of Common Stock issued pursuant to this Agreement.

 

“Warrant Certificate”
means a certificate evidencing the Warrants in the form of Attachment A.

 

5.2 Section Heading and Table of Contents
and Construction.

 

(a) Section Headings and Table of Contents,
etc. The titles of the Sections of this Agreement and any Table of Contents of this Agreement appear as a matter of convenience
only, do not constitute a part hereof and shall not affect the construction hereof. The words “herein,” “hereof,”
“hereunder” and “hereto” refer to this Agreement as a whole and not to any particular Section or other
subdivision. References to Sections are, unless otherwise specified, references to Sections of this Agreement. References to Annexes
and Attachments are, unless otherwise specified, references to Annexes and Attachments attached to this Agreement.

 

(b) Independent Construction. Each
covenant contained herein shall be construed (absent an express contrary provision herein) as being independent of each other covenant
contained herein, and compliance with any one covenant shall not (absent such an express contrary provision) be deemed to excuse
compliance with one or more other covenants.

 

5.3 Directly or Indirectly.

 

Where any provision herein refers to action
to be taken by any Person, or which such Person is prohibited from taking, such provision shall be applicable whether such action
is taken directly or indirectly by such Person, including actions taken by or on behalf of any partnership in which such Person
is a general partner.

 

5.4 Governing Law.

 

THIS AGREEMENT AND THE WARRANT CERTIFICATES
SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, AND THE RIGHTS OF THE PARTIES SHALL BE GOVERNED BY, THE INTERNAL LAWS OF THE
STATE OF NEW YORK, WITHOUT GIVING EFFECT TO THE CONFLICT OF LAWS RULES THEREOF TO THE EXTENT THAT ANY SUCH RULES WOULD REQUIRE
OR PERMIT THE APPLICATION OF THE LAWS OF ANY OTHER JURISDICTION, EXCEPT TO THE EXTENT THAT THE DELAWARE GENERAL CORPORATION LAW
SPECIFICALLY AND MANDATORILY APPLIES.

 

     

     

    

 

6. MISCELLANEOUS.

 

6.1 Condition to Effectiveness; Termination.

 

(a) The parties agree and acknowledge that,
notwithstanding anything to the contrary herein, the effectiveness of this Agreement is conditioned upon, and shall not be binding
or effective until, the occurrence of the First Merger Effective Time (as such term is defined in the Merger Agreement) in accordance
with the terms and conditions of the Merger Agreement.

 

(b) In the event that the Merger Agreement
is terminated in accordance with its terms, this Agreement shall automatically terminate and be null and void ab initio and
of no effect whatsoever, and the Original Warrant Agreement shall remain in full force and effect and shall continue to be binding
on and enforceable against the Company and the Holders.

 

6.2 Expenses.

 

Issuance of certificates for shares of Common
Stock to a holder upon the exercise of any Warrants shall be made without charge to such holder for any Tax or stamp duty in respect
of the issuance of such certificates, all of which Taxes and stamp duties shall be paid by the Company (for the avoidance of doubt,
specifically excluding the Taxes not payable by the Company pursuant to Section 3.3).

 

6.3 Amendment and Waiver.

 

This Agreement may be amended, and the observance
of any term of this Agreement may be waived, with and only with the written consent of the Company and the Required Warrantholders;
provided, however, that no amendment or waiver of the provisions of Section 2.1, this Section 6.3, Section 4
or of any term defined in Section 5.1 to the extent used in such specifically referenced Sections, may be made without the
prior written consent of all holders of Warrants then outstanding (excluding any Warrants directly or indirectly held by the Company
or any Affiliate of the Company); and, provided, further, that:

 

(a) no such amendment or waiver of any of
the provisions of this Agreement pertaining to the Exercise Price or the number of shares or kind of Common Stock that may be purchased
upon exercise of each Warrant; and

 

(b) no change accelerating the occurrence
of the Expiration Time;

 

shall be effective as to a holder of
Warrants unless consented to in writing by such holder.

 

6.4 Entire Agreement; Termination of
Original Warrant Agreement.

 

This Agreement and the Warrant Certificates
embody the entire agreement and understanding among the Company and the Holders, and supersede all prior agreements and understandings,
relating to the subject matter hereof. The Company and the Holders hereby acknowledge and agree that as of the Effective Date,
the Original Warrant Agreement and any Warrant Certificate issued thereunder are terminated and of no further force and effect
and confirm, pursuant to Section 6.2 of the Original Warrant Agreement, that all provisions thereof are terminated and of no further
force and effect and the Original Warrant Agreement and any Warrant Certificate issued thereunder are hereby superseded and replaced
by this Agreement, which amends and restates the Original Agreement and any Warrant Certificate issued thereunder in their entirety.
Each Holder shall, on or promptly following the Second Merger Effective Time, deliver and surrender to the Company any Warrant
Certificate issued under the Original Agreement in such Holder’s possession.

 

6.5 Successors and Assigns; Multiple
Holders.

 

All covenants and other agreements in this
Agreement made by or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors and
assigns of the parties hereto to the extent they become holders of Warrants (including, without limitation, any Transferee) whether
so expressed or not. Notwithstanding the foregoing sentence, the Company may not assign any of its rights, duties or obligations
hereunder or under the Warrant Certificates except pursuant to the terms of this Agreement without the prior written consent of
the Required Warrantholders.

 

Each holder of a Warrant agrees that (i)
no other holder of a Warrant will by virtue of this Warrant or exercise thereof be under any fiduciary or other duty to give or
withhold any consent or approval under this Warrant or to take any other action or omit to take any action under this Warrant and
(ii) each other holder of a Warrant may act or refrain from acting under this Warrant as such other holder may, in its discretion,
elect.

 

6.6 Notices and Information.

 

All communications hereunder or under the
Warrants shall be in writing and shall be delivered either by certified or registered mail, postage pre-paid, return receipt requested,
email or nationally recognized overnight courier, and shall be addressed to the following addresses:

 

(a) if to a Holder, at its address set forth
on Annex 2 to this Agreement, or at such other address as such Holder shall have specified to the Company in writing;

 

     

     

    

 

(b) if to any other holder of any Warrant
Certificate, addressed to such other holder at such address as such other holder shall have specified to the Company in writing
or, if any such other holder shall not have so specified an address to the Company, then addressed to such other holder in care
of the last holder of such Warrant Certificate that shall have so specified an address to the Company; and

 

(c) if to the Company, at the address set
forth on Annex 3 to this Agreement, or at such other address as the Company shall have specified to each holder of Warrants in
writing.

 

Any communication addressed and delivered
as herein provided shall be deemed to be received when actually delivered to the address of the addressee (whether or not delivery
is accepted) by a nationally recognized overnight delivery service which provides proof of delivery or on the date postmarked if
sent by registered or certified mail or upon receipt by the recipient’s email server if directed to the email address provided
in the notice section hereof, as the case may be. Any communication not so addressed and delivered shall be ineffective unless
actually received by the intended addressee. Notwithstanding the foregoing provisions of this Section 6.6, service of process
in any suit, action or proceeding arising out of or relating to this Agreement or any document, agreement or transaction contemplated
hereby shall be delivered in the manner provided in Section 6.9(c).

 

Upon exercise of any Warrant pursuant to
the terms hereof, the Company will use commercially reasonable efforts to answer a limited number of reasonable questions and provide
a limited amount of reasonable documentation regarding any non-confidential information supporting its calculation of Fully Diluted
Common Stock and the related shares of Common Stock issuable for the Denomination of such Warrant being exercised.

 

6.7 Severability.

 

Any provision of this Agreement that is
prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition
or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction
shall not invalidate or render unenforceable such provision in any other jurisdiction.

 

6.8 Execution in Counterpart.

 

This Agreement may be executed in one or
more counterparts and shall be effective when at least one counterpart shall have been executed by each party hereto, and each
set of counterparts that, collectively, show execution by each party hereto shall constitute one duplicate original.

 

6.9 Waiver of Jury Trial; Consent to
Jurisdiction, Etc.

 

(a) Waiver of Jury Trial. THE PARTIES
HERETO VOLUNTARILY AND INTENTIONALLY WAIVE ANY RIGHT ANY OF THEM MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION ARISING
OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE WARRANTS OR ANY OF THE DOCUMENTS, AGREEMENTS OR TRANSACTIONS CONTEMPLATED
HEREBY.

 

(b) Consent to Jurisdiction. ANY SUIT,
ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE WARRANTS, OR ANY OF THE DOCUMENTS, AGREEMENTS OR TRANSACTIONS
CONTEMPLATED HEREBY (WHETHER IN TORT, CONTRACT OR OTHERWISE) OR ANY ACTION OR PROCEEDING TO EXECUTE OR OTHERWISE ENFORCE ANY JUDGMENT
IN RESPECT OF ANY BREACH UNDER THIS AGREEMENT, THE WARRANTS OR ANY DOCUMENT OR AGREEMENT CONTEMPLATED HEREBY SHALL BE BROUGHT BY
SUCH PARTY IN ANY NEW YORK STATE COURT OR FEDERAL DISTRICT COURT LOCATED IN THE SOUTHERN DISTRICT OF NEW YORK AS SUCH PARTY MAY
IN ITS SOLE DISCRETION ELECT, AND BY THE EXECUTION AND DELIVERY OF THIS AGREEMENT, THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY
SUBMIT TO THE IN PERSONAM JURISDICTION OF EACH SUCH COURT, AND EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES AND AGREES NOT TO
ASSERT IN ANY PROCEEDING BEFORE ANY TRIBUNAL, BY WAY OF MOTION, AS A DEFENSE OR OTHERWISE, ANY CLAIM THAT IT IS NOT SUBJECT TO
THE IN PERSONAM JURISDICTION OF ANY SUCH COURT. IN ADDITION, EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES, TO THE FULLEST EXTENT
PERMITTED BY LAW, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE IN ANY SUIT, ACTION OR PROCEEDING ARISING
OUT OF OR RELATING TO THIS AGREEMENT OR ANY DOCUMENT, AGREEMENT OR TRANSACTION CONTEMPLATED HEREBY BROUGHT IN ANY SUCH COURT, AND
HEREBY IRREVOCABLY WAIVES ANY CLAIM THAT ANY SUCH SUIT, ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT
FORUM.

 

(c) Service of Process. EACH PARTY
HERETO IRREVOCABLY AGREES THAT PROCESS PERSONALLY SERVED OR SERVED BY U.S. REGISTERED MAIL AT THE ADDRESSES PROVIDED HEREIN FOR
NOTICES SHALL CONSTITUTE, TO THE EXTENT PERMITTED BY LAW, ADEQUATE SERVICE OF PROCESS IN ANY SUIT, ACTION OR PROCEEDING ARISING
OUT OF OR RELATING TO THIS AGREEMENT, THE WARRANTS OR ANY DOCUMENT, AGREEMENT OR TRANSACTION CONTEMPLATED HEREBY, OR ANY ACTION
OR PROCEEDING TO EXECUTE OR OTHERWISE ENFORCE ANY JUDGMENT IN RESPECT OF ANY BREACH HEREUNDER, UNDER THE WARRANTS OR UNDER ANY
DOCUMENT OR AGREEMENT CONTEMPLATED HEREBY. RECEIPT OF PROCESS SO SERVED SHALL BE CONCLUSIVELY PRESUMED AS EVIDENCED BY A DELIVERY
RECEIPT FURNISHED BY THE UNITED STATES POSTAL SERVICE OR ANY COMMERCIAL DELIVERY SERVICE.

 

[Remainder of page intentionally left
blank; next page is signature page]

 

     

     

    

 

 

IN WITNESS WHEREOF,
the Parties have executed this Agreement on the date first above written.

 

	 	COMPANY:
	 	 	 
	 	BioScrip, Inc.
	 	 	 
	 	By:	/s/ Daniel Greenleaf
	 	Name:	Daniel Greenleaf
	 	Title: 	
        President

         

     

     

    

 

 

	 	HOLDERS:
	 	 
	 	
        ASSF IV AIV B HOLDINGS, L.P.

        

        By: ASSF OPERATING MANAGER IV, L.P.

        its manager

        

        

         

         

	 	By:	/s/ Christopher Kerezsi
	 	Name:	Christopher Kerezsi
	 	Title:	Authorized Signatory
	 	 
	 	 
	 	 
	 	
        AMARI INVESTMENT PTE. LTD.

        

        By: ASSF OPERATING MANAGER IV, L.P.

        its manager

        

        

         

         

	 	By:	/s/ Christopher Kerezsi
	 	Name:	Christopher Kerezsi
	 	Title:	Authorized Signatory

 

     

     

    

 

 

	 	HOLDERS:
	 	 
	 	J.P. Morgan Securities LLC
	 	 
	 	By:	/s/ Brian M. Ercolani,
	 	Name:	Brian M. Ercolani, Asc
	 	Title:	Attorney-in-Fact
	 	 

 

 

     

     

    

 

	 	HOLDERS:
	 	 
	 	Goldman Sachs & Co. LLC
	 	 
	 	By:	/s/ Daniel Oneglia
	 	Name:	Daniel Oneglia
	 	Title:	Managing Director
	 	 

 

 

     

     

    

  

	 	HOLDERS:
	 	 
	 	
        Western Asset Middle Market Debt Fund Inc.

        Western Asset Middle Market Income Fund Inc

        By: Western Asset Management Company,

        as its Investment Manager and Agent

	 	 
	 	By:	/s/ Adam Wright
	 	Name:	Adam Wright
	 	Title:	Manager, U.S. Legal Affairs
	 	 

 

     

     

    

 

ATTACHMENT A

[FORM OF WARRANT CERTIFICATE]

 

THE SECURITIES REPRESENTED HEREBY,
AND THE SECURITIES ISSUABLE HEREBY, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE
SECURITIES LAWS AND NEITHER THE SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE
DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM
REGISTRATION UNDER SUCH ACT AND SUCH LAWS WHICH, IN THE OPINION OF COUNSEL FOR THE COMPANY, IS AVAILABLE. THE SECURITIES
REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS OF A CERTAIN AMENDED AND RESTATED WARRANT AGREEMENT, DATED AS OF
MARCH 14, 2019, THE PROVISIONS OF WHICH ARE INCORPORATED HEREIN BY REFERENCE. A COPY OF SUCH AGREEMENT IS AVAILABLE FROM THE
COMPANY UPON REQUEST.

 

WARRANT CERTIFICATE

 

BIOSCRIP, INC.

 

No. WRT- Warrants

 

Date: [ ], 20[ ]

 

This Warrant Certificate certifies that
______________________, or registered assigns, is the registered holder of Warrants entitling the owner thereof to purchase at
any time on or after the date hereof and on or prior to the Expiration Time, [ ] fully paid and nonassessable shares of Common
Stock, $0.0001 par value per share (the “Common Stock”), of BIOSCRIP, INC., a Delaware corporation (together
with its successors and assigns, the “Company”), at a purchase price (subject to adjustment as provided in the
Warrant Agreement (as defined below), the “Exercise Price”) of $2.00 per share of Common Stock upon presentation
and surrender of this Warrant Certificate to the Company with a duly executed election to purchase and payment of the Exercise
Price (including by withholding of shares of Common Stock), all in the manner set forth in the Warrant Agreement (defined below).
The Denomination of each Warrant and the Exercise Price are the Denomination and the Exercise Price as of the date hereof, and
are subject to adjustment as referred to below.

 

The Warrants are issued pursuant to an Amended
and Restated Warrant Agreement (as it may from time to time be amended or supplemented, the “Warrant Agreement”), dated
as of March 14, 2019, among the Company and the Holders named therein, and are subject to all of the terms, provisions and conditions
thereof, which Warrant Agreement is hereby incorporated herein by reference and made a part hereof and to which Warrant Agreement
reference is hereby made for a full description of the rights, obligations, duties and immunities of the Company and the holders
of the Warrant Certificates. Capitalized terms used, but not defined, herein have the respective meanings ascribed to them in the
Warrant Agreement. In the event of any conflict between this Warrant Certificate and the Warrant Agreement, the Warrant Agreement
shall control and govern.

 

As provided in the Warrant Agreement, the
Exercise Price and the Denomination evidenced by this Warrant Certificate are, upon the happening of certain events, subject to
modification and adjustment. Except as otherwise set forth in, and subject to, the Warrant Agreement, the Expiration Time of this
Warrant Certificate is as set forth in the Warrant Agreement.

 

Subject to the limitations set forth in
the Warrant Agreement, this Warrant Certificate shall be exercisable, at the election of the holder, at any time on or after the
date hereof and on or prior to the Expiration Time either as an entirety or in part from time to time. If this Warrant Certificate
shall be exercised in part, the holder shall be entitled to receive, upon surrender hereof, another Warrant Certificate or Warrant
Certificates for the Warrants not exercised. This Warrant Certificate, with or without other Warrant Certificates, upon surrender
in the manner set forth in the Warrant Agreement and subject to the conditions set forth in the Warrant Agreement, may be transferred
or exchanged for another Warrant Certificate or Warrant Certificates of like tenor evidencing Warrants entitling the holder to
a like number of shares of Common Stock as the Warrants evidenced by the Warrant Certificate or Warrant Certificates surrendered
shall have entitled such holder to purchase.

 

     

     

    

 

Except as expressly set forth in the Warrant
Agreement, no holder of this Warrant Certificate shall be entitled to vote or receive distributions or be deemed for any purpose
the holder of shares of Common Stock or of any other securities of the Company that may at any time be issued upon the exercise
hereof, nor shall anything contained in the Warrant Agreement or herein be construed to confer upon the holder hereof, as such,
any of the rights of a holder of a share of Common Stock in the Company or any right to vote upon any matter submitted to holders
of shares of Common Stock at any meeting thereof, or to give or withhold consent to any corporate action of the Company (whether
upon any recapitalization, issuance of stock, reclassification of Securities, change of par value, consolidation, merger, conveyance,
or otherwise), or to receive dividends or subscription rights, or otherwise, until the Warrant or Warrants evidenced by this Warrant
Certificate shall have been exercised as provided in the Warrant Agreement.

 

In the event of any inconsistency between
this warrant Certificate and the Warrant agreement, the terms of the Warrant Agreement shall govern.

 

THIS WARRANT CERTIFICATE SHALL BE CONSTRUED
AND ENFORCED IN ACCORDANCE WITH, AND THE RIGHTS OF THE COMPANY AND THE HOLDER HEREOF SHALL BE GOVERNED BY, THE INTERNAL LAWS OF
THE STATE OF NEW YORK, WITHOUT GIVING EFFECT TO THE CONFLICT OF LAWS RULES THEREOF TO THE EXTENT THAT ANY SUCH RULES WOULD REQUIRE
OR PERMIT THE APPLICATION OF THE LAWS OF ANY OTHER JURISDICTION, EXCEPT TO THE EXTENT THAT THE DELAWARE GENERAL CORPORATION LAW
SPECIFICALLY AND MANDATORILY APPLIES.

 

WITNESS the signature of a proper officer of the Company
as of the date first above written.

 

	 	BIOSCRIP, INC.
	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

 

     

     

    

 

 

[FORM OF ASSIGNMENT]

 

(To be executed by the registered holder
if

 

such holder desires to transfer the Warrant
Certificate)

 

 

FOR VALUE RECEIVED, ________________________ hereby sells,
assigns and transfers unto

(Please print name and address of transferee.)

 

the accompanying Warrant Certificate, together with all right,
title and interest therein, and does hereby irrevocably constitute and appoint:

 

attorney, to transfer the accompanying Warrant Certificate on
the books of the Company with full power of substitution.

Dated: , 20 .

[HOLDER]

 

By:

 

 

 

NOTICE

 

The signature to the foregoing Assignment must correspond to
the name as written upon the face of the accompanying Warrant Certificate or any prior assignment thereof in every particular,
without alteration or enlargement or any change whatsoever.

 

     

     

    

 

 

[FORM OF ELECTION TO PURCHASE]

 

(To be executed by the registered holder
if

such holder desires to exercise the Warrant
Certificate)

To: BIOSCRIP, INC.

 

The undersigned hereby irrevocably elects to exercise _____________________
Warrants represented by the accompanying Warrant Certificate to purchase the shares of Common Stock issuable upon the exercise
of such Warrants, and requests that certificates for such shares be issued in the name of:

 

(Please print name and address.)

 

(Please insert social security or other identifying number.)

 

If such number of Warrants being exercised by the undersigned
are not all the Warrants evidenced by the accompanying Warrant Certificate, a new Warrant Certificate for the balance remaining
of such Warrants shall be registered in the name of and delivered to:

 

(Please print name and address.)

 

(Please insert social security or other identifying number.)

 

The undersigned is paying the Exercise Price for the Common
Stock to be issued on exercise of the foregoing Warrants, unless payment of such Exercise Price has been waived by the Company,
by

 

[  ] certified or bank check by wire transfer, or

[  ] withholding of shares of Common Stock into which
the Warrants are being exercised.

 

Dated: , 20 .

 

[HOLDER]

 

By:

 

 

NOTICE

 

The signature to the foregoing Election to Purchase must correspond
to the name as written upon the face of the accompanying Warrant Certificate or any prior assignment thereof in every particular,
without alteration or enlargement or any change whatsoever.

 

     

     

    

 

 

ANNEX 1

Warrants Held on the Effective Date by
the Holders

 

	Holder	 	Total Number of Warrants	 
	ASSF IV AIV B Holdings, L.P.	 	 	4,520,354	 
	Amari Investments Pte. Ltd.	 	 	1,506,784	 
	J.P. Morgan Securities LLC	 	 	753,398	 
	Goldman Sachs & Co. LLC	 	 	1,130,081	 
	Western Asset Middle Market Debt Fund Inc.	 	 	113,016	 
	Western Asset Middle Market Income Fund Inc	 	 	263,683	 

 

 

     

     

    

 

ANNEX 2

Address for Holders for Notices

 

ASSF IV AIV B HOLDINGS, L.P.

ASSF IV AIV B Holdings, L.P.

c/o Ares Management LLC

2000 Avenue of the Stars, 12th Floor

Los Angeles, CA 90067

 

J.P. MORGAN SECURITIES LLC

J.P. Morgan Securities LLC

4 New York Plaza, 15th Floor, Mail Code NY1-E054

New York, New York 10004

Attention: Jeffrey L. Panzo

Email: Jeffrey.L.Panzo@JPMorgan.com

Phone No.: (212) 499-1435

 

GOLDMAN SACHS & CO. LLC

Goldman Sachs & Co. LLC

200 West Street, 26th Floor

Attn: Paul Burningham and Paige Cataruozolo

New York, New York 10282

Email: ficc-amssg-mo@gs.com

Phone No.: (917) 343-8393 (Paul Burningham),

(917) 343-3096 (Paige Cataruozolo)

 

WESTERN ASSET MIDDLE MARKET DEBT FUND INC.

WESTERN ASSET MIDDLE MARKET INCOME FUND INC

Western Asset Management Company

385 East Colorado Boulevard

Pasadena, California 91101

Attention: Legal Department

 

     

     

    

 

 

ANNEX 3

Address of Company for Notices

BioScrip, Inc.

1600 Broadway, Suite 700

Denver, CO 80202

Attn: Stephen Deitsch, Senior Vice President,

Chief Financial Officer & Treasurer

Email: Stephen.Deitsch@bioscrip.com

Telecopy Number: (720) 468-4040

 

With a copy (which shall not constitute notice) to:

Gibson, Dunn & Crutcher, LLP

200 Park Avenue

New York, New York 10036

Attention: Sean P. Griffiths

Email: sgriffiths@gibsondunn.com

Telecopy Number: (212) 251-5222

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]